Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest to treat patients with no LDL receptor function.

The candidate is unlikely to challenge other drug classes, like PCSK9 inhibitors, in larger hypercholesterolemia populations, however, given the availability of effective and cheap treatment options for those patients...